Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Mircera (methoxy polyethylene glycol-epoetin beta) for the treatment of anaemia associated with chronic kidney ...

-- Findings Illustrate Role of Innovative New Treatment in Population Most Affected by Chronic Kidney Disease A new Roche Phase III analysis shows once-monthly MIRCERA, a continuous erythropoietin ...

being a common adverse event and a burden for patients with chronic kidney disease (CKD).

BASEL, Switzerland, May 25 /PRNewswire/ -- Roche announced today that it has received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) recommending a ...

who are converted to treatment with MIRCERA. The safety and efficacy of MIRCERA therapy in other indications has not been established. When approved by the European Commission, MIRCERA will become the ...